Back

Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials

European Journal of Preventive Cardiology

22 December 2021
Organised by: Logo
Read full article
ESC Journals

Contributors

Mei Qiu
Mei Qiu

Author

Xu-Bin Wei
Xu-Bin Wei

Author

Wei Wei
Wei Wei

Author

You may be interested in
thumbnail
Congress Presentation
Effects of the glucagon like peptide-1 receptor analogue, sodium-glucose co-transporter 2 and their combination on myocardial work index and vascular function in diabetes after 3-month treatment
3 September 2019
thumbnail
Congress Presentation
GLP-1 receptor and cardiovascular outcomes among patients with diabetes on dialysis:– insights from the TriNetX real-world database
31 August 2026
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025
thumbnail
Congress Presentation
Efficacy of additional medical therapies in patients with heart failure, a reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources